Last reviewed · How we verify

DTaP IPV HB PRP~T vaccine — Competitive Intelligence Brief

DTaP IPV HB PRP~T vaccine (DTaP IPV HB PRP~T vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

phase 3 vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

DTaP IPV HB PRP~T vaccine (DTaP IPV HB PRP~T vaccine) — Sanofi Pasteur, a Sanofi Company. This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DTaP IPV HB PRP~T vaccine TARGET DTaP IPV HB PRP~T vaccine Sanofi Pasteur, a Sanofi Company phase 3 vaccine
Comirnaty BNT162b2 (tozinameran) Pfizer Inc. marketed vaccine SARS-CoV-2 virus 2021-08-23
Prevnar 20 pneumococcal 20-valent conjugate vaccine (PCV20) Pfizer Inc. marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (20 serotypes) 2021-06-08
Vaccine Support Cp Vaccine administration Women and Infants Hospital of Rhode Island marketed vaccine unknown
TT TT CanSino Biologics Inc. marketed Viral vector vaccine SARS-CoV-2 spike protein
RSV prefusion F protein-based vaccine rsv-prefusion-f-protein-based-vaccine Pfizer Inc. marketed Viral protein subunit vaccine Respiratory syncytial virus fusion (F) protein
Tozinameran 12 Years of age and older tozinameran-12-years-of-age-and-older Pfizer marketed vaccine SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (vaccine class)

  1. Pfizer · 20 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
  3. GlaxoSmithKline · 12 drugs in this class
  4. Merck Sharp & Dohme LLC · 12 drugs in this class
  5. Centers for Disease Control and Prevention · 9 drugs in this class
  6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
  7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
  8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
  9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
  10. Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DTaP IPV HB PRP~T vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/dtap-ipv-hb-prp-t-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: